Evaluate patients suspected of having polymyositis, dermatomyositis, or polymyositis-scleroderma overlap syndrome.

Anti-Jo-1 antibodies are present in approximately 20% to 30% of patients with adult-onset polymyositis syndromes. They are present in >65% of patients with both myositis and interstitial lung disease. In such patients, the presence of anti-Jo-1 antibodies may be predictive of a response to steroid treatment. Testing for ANAs is not adequate for the detection of anti-Jo-1 antibodies.

Bernstein RM, Morgan SH, Chapman J, et al. Anti-Jo-1 antibody: A marker for myositis with interstitial lung disease. Br Med J (Clin Res Ed). 1984 Jul 21; 289(6438):151-152. PubMed 6430389

Hochberg MC, Feldman D, Stevens MB, Arnett FC, Reichlin M. Antibody to Jo-1 in polymyositis/dermatomyositis: Association with interstitial pulmonary disease. J Rheumatol. 1984 Oct; 11(5):663-665. PubMed 6334746